Core Viewpoint - The announcement details a significant ownership change in Chengzhi Co., with the indirect controlling shareholder, Qingdao Haikong Investment Holdings Co., transferring 100% of its shares in Chengzhi to its wholly-owned subsidiary, Dongjiakou Group, which will indirectly acquire 30.83% of Chengzhi's shares [1][2]. Group 1: Ownership Change - Dongjiakou Group has signed an agreement to acquire 100% of Qingdao Haikong Investment Holdings Co. without any monetary compensation, only incurring necessary fees as per national regulations [2]. - Prior to this acquisition, Dongjiakou Group did not hold any shares in Chengzhi, while Chengzhi Kairong, the current controlling shareholder, holds 375 million shares, representing 30.83% of the total share capital [1][2]. Group 2: Business Operations - Chengzhi Co. operates in industrial gases, basic chemical raw materials, semiconductor display materials, life science products, and industrial hemp cultivation and processing [2]. - The company reported a revenue of 11.066 billion yuan and a net profit of 231 million yuan for the fiscal year 2024, marking a year-on-year increase of 29.98% [2]. Group 3: Strategic Integration - The acquisition aims to promote internal strategic integration within Haikong Group, transferring ownership of Haikong Investment Holdings to Dongjiakou Group [1][2]. - There is no indication of competitive conflict between the businesses of the acquirer and Chengzhi, ensuring no adverse effects on the company's operations or minority shareholders [3].

IM Cannabis (IMCC) Q1 2025 Earnings Call May 15, 2025 09:00 AM ET Company Participants Anna Taranko - Director - Investor & Public RelationsOren Shuster - CEO & ChairmanUri Birenberg - Chief Financial Officer Conference Call Participants None - Analyst Operator Good morning, and welcome to I'm Cannabis' First Quarter twenty twenty five Earnings Conference Call. Today's conference call is being recorded. At this time, I would like to turn the conference over to Anna Taranko, Director of Investor and public r ...

Company Performance - OrganiGram reported a quarterly loss of $0.13 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.03, representing an earnings surprise of -333.33% [1] - The company posted revenues of $29.76 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 29.59%, compared to revenues of $27.91 million a year ago [2] - Over the last four quarters, OrganiGram has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Outlook - OrganiGram shares have declined approximately 26.7% since the beginning of the year, while the S&P 500 has decreased by -3.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $45.73 million, and for the current fiscal year, it is -$0.16 on revenues of $166.74 million [7] - The estimate revisions trend for OrganiGram is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Products industry, to which OrganiGram belongs, is currently in the bottom 33% of over 250 Zacks industries, suggesting a challenging environment [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact OrganiGram's stock performance [5]